Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23551319 | 1.00 | CRBN (0.49) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL23551320 | 1.00 | CRBN (0.49) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL29535371 | 1.00 | CRBN (0.49) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL23540366 | 1.00 | CRBN (0.49) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL30120231 | 1.00 | CRBN (0.49) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL24754108 | 0.97 | CRBN (0.46) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL30120220 | 0.97 | CRBN (0.46) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL23551339 | 0.90 | DDB1 (0.49) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL23551344 | 0.89 | DDB1 (0.47) | CRBNDDB1HDAC8HDAC3HDAC1 | |
| SCHEMBL24752831 | 0.88 | CRBN (0.45) | CRBNDDB1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |